Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Low-Dose Aspirin May Lower Risk of Hepatocellular Carcinoma & Liver-Related Mortality

March 16, 2020
By Hannah Slater
Article

A nationwide study found that low-dose aspirin was associated with a significantly lower risk of hepatocellular carcinoma and lower liver-related mortality compared to no aspirin use, without a significantly higher risk of gastrointestinal bleeding.

A nationwide study of patients with chronic viral hepatitis, published in The New England Journal of Medicine, found that low-dose aspirin was associated with a significantly lower risk of hepatocellular carcinoma and lower liver-related mortality compared to no aspirin use, without a significantly higher risk of gastrointestinal bleeding.1 

This finding supports the need for randomized clinical trials designed to test the benefits of aspirin for primary prevention of hepatocellular carcinoma. 

“Rates of liver cancer and of mortality from liver disease are rising at an alarming pace in US and European countries,” lead author Tracey Simon, MD, MPH, investigator in the division of gastroenterology and hepatology at Massachusetts General Hospital, said in a press release.2 “Despite this, there remain no established treatments to prevent the development of liver cancer, or to reduce the risk of liver-related death.”

Researchers used nationwide Swedish registries to identify 50,275 adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 2015 and who did not have a history of aspirin. They then identified 14,205 patients who were starting to take low-dose aspirin based on their first filled prescriptions for 90 or more consecutive doses of aspirin. Using these data, Cox proportional-hazards regression modeling was used to estimate the risk of hepatocellular carcinoma and liver-related mortality, accounting for competing events.

With a median of 7.9 years of follow-up, the estimated cumulative incidence of hepatocellular carcinoma was found to be 4.0% among aspirin users and 8.3% among non-users of aspirin (difference, -4.3 percentage points; 95% CI, -5.0 to -3.6; adjusted HR, 0.69; 95% CI, 0.62-0.76). This inverse correlation seemed to be duration-dependent, given that compared with short-term use (3 months to <1 year), the adjusted HRs were 0.90 (95% CI, 0.76-1.06) for 1 to <3 years of use, 0.66 (95% CI, 0.56-0.78) for 3 to <5 years of use, and 0.57 (95% CI, 0.42-0.70) for 5 or more years of use.

Moreover, 10-year liver-related mortality was 11.0% among aspirin users and 17.9% among nonusers (difference, -6.9 percentage points [95% CI, -8.1 to -5.7]; adjusted HR, 0.73; 95% CI, 0.67-0.81). However, the 10-year risk of gastrointestinal bleeding did not differ significantly between those who did and did not use aspirin (7.8% and 6.9%, respectively; difference, 0.9 percentage points; 95% CI, -0.6 to 2.4). Further, the benefits observed were seen regardless of sex, cause of hepatitis, or underlying compensated cirrhosis, suggesting that the benefits may apply to a broad at-risk population.

“By applying inverse probability of treatment weighting approaches to an unselected population with confirmed viral hepatitis and detailed clinical and medication use data, the current study provides more compelling evidence of the potential hepatoprotective benefits of aspirin,” the authors wrote. “The consistent duration-response associations lend further credence to a potential causal relationship.” 

According to the study, more than 500,000 cases of incident hepatocellular carcinoma are diagnosed each year, primarily related to chronic infection with hepatitis B or hepatitis C virus. Additionally, since the 1990s, the incidences of cirrhosis and hepatocellular carcinoma have dramatically increased in the US and Europe, and mortality from hepatocellular carcinoma is increasing more quickly than that from any other cancer.

References:

1. Simon TG, Duberg A, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. The New England Journal of Medicine. doi:10.1056/NEJMoa1912035.

2. Low-dose aspirin linked to reduced liver cancer risk [news release]. Boston, Massachusetts. Published March 12, 2020. eurekalert.org/pub_releases/2020-03/mgh-lal031220.php. Accessed March 13, 2020.

Recent Videos
4 experts in this video
4 experts in this video
Related Content
Advertisement

Samples were analyzed using 40-GEP clinical testing standard operating procedures. The trial end points were LRFS and MFS.

DecisionDx-SCC Predicts Recurrence, Guides Imaging in Squamous Cell Carcinoma

Tim Cortese
August 26th 2025
Article

Two studies were recently published that validated the use of the DecisionDx-SCC test as a tool for the treatment of cutaneous squamous cell carcinoma.


Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 25th 2025
Podcast

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.


The AML Epigenomic Risk model used 946 AML-only peripheral blood or bone marrow samples at diagnosis.

AI Prognostic Tool Confirms Concordance Through Epigenomic Signatures in AML

Tim Cortese
August 26th 2025
Article

Both experimental models significantly improved upon historical clinical risk trial groups for patients with acute myeloid leukemia.


Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO; and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.


Developers will now initiate the phase 3 MarsLight-11 trial of IBI363 among patients with immunotherapy-resistant squamous non–small cell lung cancer.

FDA Clears IND for IBI363 in Squamous Non–Small Cell Lung Cancer

Russ Conroy
August 25th 2025
Article

Developers will now initiate the phase 3 MarsLight-11 trial of IBI363 among patients with immunotherapy-resistant squamous non–small cell lung cancer.


High levels of long-lasting, multifunctional HPV16-specific CD8-positive T cells induced by PDS0101 promoted durable patient survival.

PDS0101 Plus Pembrolizumab Yields Positive Survival Results in HNSCC

Tim Cortese
August 25th 2025
Article

The median overall survival was 39.3 months with PDS0101 plus pembrolizumab in those with front-line recurrent or metastatic head and neck squamous cell carcinoma.

Related Content
Advertisement

Samples were analyzed using 40-GEP clinical testing standard operating procedures. The trial end points were LRFS and MFS.

DecisionDx-SCC Predicts Recurrence, Guides Imaging in Squamous Cell Carcinoma

Tim Cortese
August 26th 2025
Article

Two studies were recently published that validated the use of the DecisionDx-SCC test as a tool for the treatment of cutaneous squamous cell carcinoma.


Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 25th 2025
Podcast

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.


The AML Epigenomic Risk model used 946 AML-only peripheral blood or bone marrow samples at diagnosis.

AI Prognostic Tool Confirms Concordance Through Epigenomic Signatures in AML

Tim Cortese
August 26th 2025
Article

Both experimental models significantly improved upon historical clinical risk trial groups for patients with acute myeloid leukemia.


Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO; and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.


Developers will now initiate the phase 3 MarsLight-11 trial of IBI363 among patients with immunotherapy-resistant squamous non–small cell lung cancer.

FDA Clears IND for IBI363 in Squamous Non–Small Cell Lung Cancer

Russ Conroy
August 25th 2025
Article

Developers will now initiate the phase 3 MarsLight-11 trial of IBI363 among patients with immunotherapy-resistant squamous non–small cell lung cancer.


High levels of long-lasting, multifunctional HPV16-specific CD8-positive T cells induced by PDS0101 promoted durable patient survival.

PDS0101 Plus Pembrolizumab Yields Positive Survival Results in HNSCC

Tim Cortese
August 25th 2025
Article

The median overall survival was 39.3 months with PDS0101 plus pembrolizumab in those with front-line recurrent or metastatic head and neck squamous cell carcinoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.